November 21, 2023
Alkermes to Participate in Two Upcoming Investor Conferences
November 15, 2023
Alkermes Completes Separation of Oncology Business
November 07, 2023
Alkermes to Participate in the Jefferies London Healthcare Conference
Blair Jackson shares his thoughts on Alkermes' past and future as a neuroscience company.
Hear from Steve Schiavo on Alkermes' dedication to supporting employees as they care for loved ones.
Alkermes leverages its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.